The core technology was developed by the companies within the consortium spearheaded by Richard Cornell. It is an advanced formulation of bioactive glasses, which has been designed from the start to optimise its various functions - unlike our competitors.
​
The two key functions are: A) to stimulate new bone tissue, and B) to fight infection by being bactericidal to key pathogens without the use of antibiotics.
​
These products are categorised as medical devices and not pharmaceuticals.
Our Core Technology
Key Products
Granules
Our complex formulation of bioactive glasses has been designed and optimised to: A) Stimulate new bone formation, while B) being powerfully bactericidal (over 3-log10 over 7 days) against key gram-positive and gram-negative bacteria.
​
Of the many uses of this product, there is a large market in the treatment of open fractures.
Injectable Paste
The University of Sheffield are developing a paste to deliver our granules as an injectable paste. The design process has carefully selected and optimised the carrier to ensure both the promotion of bone healing, and the bactericidal properties are not adversely affected. They are also exploring a wide range of design opportunities that this paste offers.
​
There are many indications for clinical use of this product with spinal surgery opening up a larger market.
We are working with the University of Leeds to take full advantage of the design freedoms offered by our advanced bioactive glass formulations. In the controlled-release products each of the functions will be paced to suit treatment requirements.
​
These exciting products can be used in a wide range of treatments. Its use in revision surgery of infected total joint replacement has a particularly large market.
Controlled Release